Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment.
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
03 02 2020
03 02 2020
Historique:
received:
20
08
2019
accepted:
16
01
2020
entrez:
5
2
2020
pubmed:
6
2
2020
medline:
15
5
2021
Statut:
epublish
Résumé
Despite the efficacy of immune checkpoint inhibitors (ICIs) only the 20-30% of treated patients present long term benefits. The metabolic changes occurring in the gut microbiota metabolome are herein proposed as a factor potentially influencing the response to immunotherapy. The metabolomic profiling of gut microbiota was characterized in 11 patients affected by non-small cell lung cancer (NSCLC) treated with nivolumab in second-line treatment with anti-PD-1 nivolumab. The metabolomics analyses were performed by GC-MS/SPME and Four out of 11 patients (36%) presented early progression, while the remaining 7 out of 11 (64%) presented disease progression after 12 months. 2-Pentanone (ketone) and tridecane (alkane) were significantly associated with early progression, and on the contrary short chain fatty acids (SCFAs) (i.e., propionate, butyrate), lysine and nicotinic acid were significantly associated with long-term beneficial effects. Our preliminary data suggest a significant role of gut microbiota metabolic pathways in affecting response to immunotherapy. The metabolic approach could be a promising strategy to contribute to the personalized management of cancer patients by the identification of microbiota-linked "indicators" of early progressor and long responder patients.
Sections du résumé
BACKGROUND
Despite the efficacy of immune checkpoint inhibitors (ICIs) only the 20-30% of treated patients present long term benefits. The metabolic changes occurring in the gut microbiota metabolome are herein proposed as a factor potentially influencing the response to immunotherapy.
METHODS
The metabolomic profiling of gut microbiota was characterized in 11 patients affected by non-small cell lung cancer (NSCLC) treated with nivolumab in second-line treatment with anti-PD-1 nivolumab. The metabolomics analyses were performed by GC-MS/SPME and
RESULTS
Four out of 11 patients (36%) presented early progression, while the remaining 7 out of 11 (64%) presented disease progression after 12 months. 2-Pentanone (ketone) and tridecane (alkane) were significantly associated with early progression, and on the contrary short chain fatty acids (SCFAs) (i.e., propionate, butyrate), lysine and nicotinic acid were significantly associated with long-term beneficial effects.
CONCLUSIONS
Our preliminary data suggest a significant role of gut microbiota metabolic pathways in affecting response to immunotherapy. The metabolic approach could be a promising strategy to contribute to the personalized management of cancer patients by the identification of microbiota-linked "indicators" of early progressor and long responder patients.
Identifiants
pubmed: 32014010
doi: 10.1186/s12967-020-02231-0
pii: 10.1186/s12967-020-02231-0
pmc: PMC6998840
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
49Références
Biosci Biotechnol Biochem. 2012;76(4):679-84
pubmed: 22484930
J Nutr. 2013 Oct;143(10):1549-57
pubmed: 23946343
J Thorac Dis. 2013 Oct;5 Suppl 5:S540-50
pubmed: 24163746
Nat Commun. 2016 Feb 02;7:10391
pubmed: 26837003
FEMS Microbiol Ecol. 2018 Sep 1;94(9):
pubmed: 29982420
Environ Microbiol. 2017 Jan;19(1):29-41
pubmed: 27928878
Lung Cancer (Auckl). 2017 May 17;8:31-38
pubmed: 28553152
Science. 2018 Feb 2;359(6375):582-587
pubmed: 29217585
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
J Natl Compr Canc Netw. 2017 Jul;15(7):863-866
pubmed: 28687573
FASEB J. 2007 Jun;21(8):1675-88
pubmed: 17314143
Diabetes Care. 2018 Mar;41(3):398-405
pubmed: 29212824
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
J Breath Res. 2019 Apr 24;13(3):034002
pubmed: 30822771
PLoS One. 2018 Dec 6;13(12):e0208171
pubmed: 30521551
Open Biochem J. 2010 May 13;4:53-8
pubmed: 20563285
PLoS One. 2013 Apr 22;8(4):e61217
pubmed: 23630581
Nutr Res Rev. 2015 Jun;28(1):42-66
pubmed: 26156216
Annu Rev Nutr. 2008;28:115-30
pubmed: 18429699
J Oncol. 2017;2017:5035371
pubmed: 29075294
Science. 2012 Jun 8;336(6086):1262-7
pubmed: 22674330
Genome Biol. 2014;15(12):550
pubmed: 25516281
J Agric Food Chem. 2019 Feb 6;67(5):1381-1391
pubmed: 30644740
Cancer Res. 1994 Jun 15;54(12):3288-93
pubmed: 8205551
Appl Environ Microbiol. 2006 Jul;72(7):5069-72
pubmed: 16820507
Sci Transl Med. 2014 May 28;6(238):238ra70
pubmed: 24871131
Oncotarget. 2018 Apr 3;9(25):17915-17927
pubmed: 29707157
Am J Clin Nutr. 2013 May;97(5):1044-52
pubmed: 23553152
Expert Opin Drug Metab Toxicol. 2014 Jul;10(7):915-9
pubmed: 24905565
Exp Mol Med. 2018 Dec 13;50(12):165
pubmed: 30546008
Nat Genet. 2018 Jun;50(6):790-795
pubmed: 29808030
Free Radic Biol Med. 2015 Aug;85:219-27
pubmed: 25881551
Front Pediatr. 2014 Jan 28;2:6
pubmed: 24479111
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
PLoS One. 2014 Oct 21;9(10):e111228
pubmed: 25333938
Medicine (Baltimore). 2018 Dec;97(50):e13676
pubmed: 30558074
Front Microbiol. 2019 May 31;10:1206
pubmed: 31214145
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
Science. 2015 Nov 27;350(6264):1084-9
pubmed: 26541606
Xenobiotica. 1999 Nov;29(11):1181-9
pubmed: 10598751
J Immunother Cancer. 2019 Apr 17;7(1):108
pubmed: 30995949
Bioinformatics. 2010 Jan 15;26(2):266-7
pubmed: 19914921
Front Microbiol. 2018 Sep 19;9:2147
pubmed: 30283410
Nucleic Acids Res. 2013 Jan;41(Database issue):D801-7
pubmed: 23161693
Science. 2015 Nov 27;350(6264):1079-84
pubmed: 26541610
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
Neoplasia. 2017 Oct;19(10):848-855
pubmed: 28923537
Cell. 2008 Sep 5;134(5):714-7
pubmed: 18775301
Immunology. 2018 Jun;154(2):220-229
pubmed: 29569377
Nat Methods. 2010 May;7(5):335-6
pubmed: 20383131
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Front Cell Infect Microbiol. 2012 Dec 11;2:156
pubmed: 23248777
Genome Med. 2018 Oct 31;10(1):78
pubmed: 30376889
J Pathol Transl Med. 2019 Jul;53(4):199-206
pubmed: 31042863
PLoS One. 2010 Jan 27;5(1):e8819
pubmed: 20111698
Angew Chem Int Ed Engl. 2010 Jul 26;49(32):5426-45
pubmed: 20629054